Results of hypofractionated whole brain radiotherapy (2x8 Gy) for patients with brain metastases from lung cancer

被引:0
|
作者
Ozkok, S. [1 ]
Bolukbasi, Y. [1 ]
Akcay, C. Akay [1 ]
Yalman, D. [1 ]
机构
[1] Ege Univ, Sch Med, Dept Radiat Oncol, TR-35100 Izmir, Turkey
来源
JOURNAL OF BUON | 2011年 / 16卷 / 02期
关键词
brain metastases; 2x8; Gy; non small cell lung cancer; palliative radiotherapy; small cell lung cancer; THERAPY ONCOLOGY GROUP; PARTITIONING ANALYSIS RPA; PROGNOSTIC-FACTORS; RADIATION-THERAPY; CEREBRAL METASTASES; RANDOMIZED-TRIAL; GROUP RTOG; IRRADIATION; SURVIVAL; INDEX;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the clinical and radiologic response rates, toxicity and tolerability of 2x8 Gy whole brain radiotherapy (WBRT) in lung cancer patients with brain metastases (BM). Methods: WBRT was delivered to 126 lung cancer patients with BM during 2002-2006. External beam RT was delivered with a fraction dose of 8 Gy on the same day of each consecutive week Tumor and symptom response and toxicity were recorded at every follow-up. Recursive partitioning analysis (RPA) and the new Graded Prognostic Assessment (GPA) were used for analysis of overall survival (OS). Results: Twenty-three patients had small cell (SCLC) and 103 had non small cell lung cancer Pretreatment median Karnofsky performance score (KPS) was 70 (range 20-90). Clinical response rates were as follows: complete 31%; good partial 30.2%; partial 21.4%; stable 7.9%; and progressive 5.6%. Median palliation and survival duration was 57 and 80 days, respectively. Two- and 6-month survival rates (SR) were 59.5% and 25.4%, respectively. According to recursive partitioning analysis (RPA) 6-month SR for groups 1, 2 and 3 were 61.5, 41.6 and 33.9%, respectively (p=0.002). Six-month SR for the new Graded Prognostic Assessment (GPA) were: GPA 0-1, 7%; GPA 1.5-2.5, 34.2%; GPA 3, 25%; and GPA 3.5-4.0, 66.6% (p=0.0003). Conclusion: 2x8 Gy WBRT was found to be feasible. However the late morbidity of this schedule is unknown so its use could be restricted to patients with poor performance status, with a short life expectancy and/or social problems, unlikely to tolerate more protracted radiotherapy regimens.
引用
收藏
页码:233 / 240
页数:8
相关论文
共 50 条
  • [41] Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival
    Frisk, Gabriella
    Frankling, Maria Helde
    Warnqvist, Anna
    Bjorkhem-Bergman, Linda
    Hedman, Mattias
    LIFE-BASEL, 2022, 12 (04):
  • [42] Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastases
    Luo, S.
    Meng, L.
    Li, P.
    Gong, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S621 - S621
  • [43] Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost
    Tian-Qi Du
    Xiang Li
    Wei-Si Zhong
    Jian-Dong Tian
    Yu-Xia Zhao
    Dan Liu
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 569 - 577
  • [44] Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost
    Du, Tian-Qi
    Li, Xiang
    Zhong, Wei-Si
    Tian, Jian-Dong
    Zhao, Yu-Xia
    Liu, Dan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (02) : 569 - 577
  • [45] Preliminary results of whole brain radiotherapy with concurrent trastuzumab as a potential radiosensitiser for treatment of brain metastases in breast cancer patients
    Chargari, C.
    Idrissi, H. Riahi
    Pierga, J.
    Bollet, M.
    Dieras, V.
    Campana, F.
    Cottu, P.
    Fourquet, A.
    Kirova, Y.
    JOURNAL OF NEUROLOGY, 2011, 258 : 49 - 50
  • [46] PRELIMINARY RESULTS OF WHOLE BRAIN RADIOTHERAPY WITH CONCURRENT TRASTUZUMAB AS A POTENTIAL RADIOSENSITIZER FOR TREATMENT OF BRAIN METASTASES IN BREAST CANCER PATIENTS
    Chargari, C.
    Idrissi, H. Riahi
    Pierga, J. Y.
    Bollet, M.
    Dieras, V.
    Campana, F.
    Cottu, P.
    Fourquet, A.
    Kirova, Y.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S244 - S244
  • [47] Efficacy of Temozolomide Combined with Whole Brain Radiotherapy in the Treatment of Cerebral Metastases from Lung Cancer
    Lei ZHAO
    Ping SUN
    Medicinal Plant, 2017, (03) : 56 - 58
  • [48] Effects of Whole Brain Radiotherapy for Brain Metastases from Lung Adenocarcinoma with or without EGFR Mutations
    Li, Hongwei
    Zhang, Xiaqin
    Jia, Sufang
    Jia, Haixia
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1518 - S1518
  • [49] A Phase 2 Trial of Whole-brain Radiotherapy Combined With Intravenous Chemotherapy in Patients With Brain Metastases From Breast Cancer
    Cassier, Philippe A.
    Ray-Coquard, Isabelle
    Sunyach, Marie-Pierre
    Lancry, Laurence
    Guastalla, Jean-Paul
    Ferlay, Celine
    Gomez, Frederic
    Cure, Herve
    Lortholary, Alain
    Claude, Line
    Blay, Jean-Yves
    Bachelot, Thomas
    CANCER, 2008, 113 (09) : 2532 - 2538
  • [50] Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Lung Cancer: Dose-Response Effect and Toxicity
    Pan, K.
    Zhu, L.
    Wang, B.
    Xu, X.
    Ma, S.
    Xia, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S500 - S500